CD64 and Antibiotics in Human Sepsis

University of Ulm64 enrolled

Overview

The purpose of the study is to find out whether CD64 expression on neutrophils measured by a new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis.

In the present study, in critically ill patients with suspected infection undergoing application of antibiotics, CD64 and inflammatory plasma markers will be determined on days 1 to 4. CD64 expression on the surface of neutrophils will be determined by fluorescence activated cell sorter (FACS) and with a new bedside test (LeukoDx). The purpose of the study is to clarify: 1. Is CD64 expression on neutrophils associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis? 2. Is CD64 expression associated with distinct plasma parameters of inflammation? 3. Do the results of the gold standard CD64 determination by FACS correlate with those of a new bedside test (LeukoDx)?

Study Type

OBSERVATIONAL

Enrollment

Conditions

Antibiotic Resistant Infection Critical Illness SIRS Sepsis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \> 18 years * critically ill adult patients * sepsis * SIRS * initiation of antibiotic treatment * patients \< 48 hours after admission on ICU Exclusion Criteria: * multiple admissions on ICU, (\>1 in last 2 weeks period) * leukopenia \< 1 G/l * and thrombocytopenia * rhG-CSF or IFN-gamma therapy up to 1 week before inclusion * participation in another study receiving drugs or biological within the preceeding 30 days * recent longterm corticosteroid treatment * HIV * patients after organ transplantation treated with immunomodulating drugs * pregnant patients or after delivery * life expectancy \< 24 hours * polytraumatized patients with reanimation on scene, or infest prognosis * patients under high dose corticosteroids or chemotherapy

Locations (1)

Department of Anaesthesiology, University Hospital Ulm

Ulm, Germany

Outcomes

Primary Outcomes

CD64 expression on neutrophils measured by LeukoDx

Time frame: 1 year

Secondary Outcomes

Association of course of CD64 expression with effective antibiotic treatment

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.